From 2012 through 2020, Medicare and Medicaid spent $40 billion on drugs that received accelerated approvals from 2012 to 2017 and were later converted to standard FDA approvals based on clinical trials that evaluated surrogate endpoints, and the government spent another $14 billion on accelerated approval drugs that were not converted to standard approvals, according to a study published in the Journal of the American Medical Association . “These findings suggest that drugs that are granted accelerated approval were...